Roger Lo on the Evolution of Melanoma During Therapy

Article

Roger Lo, MD, PhD, UCLA Jonsson Comprehensive Cancer Center, discusses the evolution of metastatic melanoma during therapy.

Roger Lo, MD, PhD, UCLA Jonsson Comprehensive Cancer Center, discusses the evolution of metastatic melanoma during therapy.

Because of mutations in the BRAF gene, patients become resistant to anti-BRAF treatment after a period of time and the tumors start to grow again.

Lo and investigators used genomic and epigenomic profiling to detect changes in the genes’ activities inside the tumor and evaluate the function of the immune cells.

They found that the altered tumor cell behavior originates from the gene activity regulatory mechanism called CpG methylation.

Related Videos
Elizabeth Aronson
MPN-Associated Anemia: What Nurses Should Look Out For
Cancer-Related Cognitive Impairment
Charina Toste
Lindsey Lyle
Alyssa Ridad
Yelena Shames
Johanna Garibaldi
Elizabeth Cullen
Related Content
© 2023 MJH Life Sciences

All rights reserved.